Canopy Growth’s June Tightrope Walk: From Balance-Sheet Correction to a US Policy Milestone
10.06.2026 - 18:25:33 | boerse-global.de
A botched accounting classification and a long-awaited US regulatory hearing collide this month for Canopy Growth, pressing the cannabis group into a high-stakes stretch that will test investors’ patience. The stock, which has shed more than half its value since peaking in December 2025, now faces a two-front challenge: a forced financial restatement due June 15 and a DEA hearing on recreational cannabis rescheduling set for June 29. Neither event offers a quick fix.
The accounting snag that froze insider trades
The restatement stems from an error in how the company classified warrants. Canopy Growth had recorded options with US-dollar exercise prices as equity when, under Canadian-dollar accounting rules, they should have been booked as liabilities. The mistake carries no cash impact, but it rearranges the balance-sheet structure. The Ontario Securities Commission responded by imposing a Management Cease Trade Order on May 28, barring executives from trading the stock until corrected figures are published.
That correction arrives alongside the fiscal-year results on June 15. CEO Luc Mongeau and CFO Tom Stewart will host a webcast at 4 pm CET that day. The market will be watching for both the adjusted prior-year numbers and a credible path toward profitability in the current one.
Market doubts already baked into the price
Canopy Growth has been drifting. The shares last changed hands at roughly €0.89 in Europe, placing them 55% below the 52-week high of €2.00 reached last December. The stock now trades 13.5% beneath its 200-day moving average of €1.04, a sign that the recent sideways move is probably a pause in a broader downtrend rather than the start of a recovery. Year to date, the equity has lost about 13% of its value.
Should investors sell immediately? Or is it worth buying Canopy Growth?
Short-term gains are elusive. A 0.65% rise on the day of the primary article barely registered. The broader picture, as the primary source notes, is that the era of “vague options” rewarding shareholders is over. The market is demanding concrete execution, not legislative what-ifs.
Rescheduling: already a mixed blessing for Canopy
The US Drug Enforcement Administration’s April decision to move cannabis from Schedule I to Schedule III boosted the sector briefly, but the gains evaporated within the same session. The problem for Canopy is structural: the rescheduling covers only medical cannabis, not recreational use. Moreover, the company holds only a non-controlling minority stake in its US vehicle, Canopy USA. Until it consolidates a majority interest, the benefits of the eased classification remain out of reach.
The June 29 hearing opens the door to broader reform on recreational cannabis. But it is a formal process, not an automatic policy shift, and any outcome remains uncertain. Investors have learned to separate regulatory noise from operational reality.
Operational carrots, but also deep dilution
On the ground, Canopy is pushing ahead. The acquisition of MTL Cannabis closed in March 2026, strengthening its Canadian medical-flower platform and premium-bud offering. In Germany, where the medical cannabis market is approaching €1 billion in annual sales, the company plans to roll out five new MTL strains this month, with more to follow later in the year. Germany’s imports, however, have cooled, tempering the European growth story.
The bull case rests on margins and cash flow. Management has set a target of positive adjusted EBITDA by fiscal 2027, backed by cost cuts and a narrower focus. But the math is complicated by a 163% increase in the share count over the past year, to roughly 378 million shares. That dilution eats into per-share metrics and makes even modest earnings progress harder to achieve.
Canopy Growth at a turning point? This analysis reveals what investors need to know now.
Analyst opinions reflect the uncertainty. ATB Cormark Capital Markets upgraded the stock from “Strong Sell” to “Moderate Buy” in March, while Canaccord Genuity started coverage with a “Buy” rating that same month. Weiss Ratings, however, kept its sell call in June, albeit at a slightly less negative level. The divergence captures how little consensus exists around Canopy’s turnaround.
The 15th of June will provide the first hard data point in months. If the restated figures and the forward guidance manage to rebuild some trust, the stock could find a floor. If not, the gap between the €0.89 price and the December high of €2.00 may well widen further.
Ad
Canopy Growth Stock: New Analysis - 10 June
Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
